Financial Performance - Operating revenue increased by 6.70% to CNY 20,859,112.75 for the first quarter of 2024, up from CNY 19,549,204.28 in the same period last year[10]. - Net profit attributable to shareholders decreased by 91.35% to a loss of CNY 9,055,465.07, compared to a loss of CNY 4,732,374.92 in Q1 2023[10]. - Total operating revenue for Q1 2024 reached ¥20,859,112.75, an increase of 6.7% compared to ¥19,549,204.28 in Q1 2023[42]. - Net loss for Q1 2024 was ¥9,055,465.07, compared to a net loss of ¥5,017,164.38 in Q1 2023, reflecting a deterioration in profitability[43]. - Basic and diluted earnings per share for Q1 2024 were both -¥0.11, compared to -¥0.06 in Q1 2023, indicating worsening earnings performance[43]. - The company reported a total comprehensive loss of ¥9,055,465.07 for Q1 2024, compared to a comprehensive loss of ¥5,017,164.38 in Q1 2023[43]. Assets and Liabilities - Total assets decreased by 4.21% to CNY 463,378,563.81 as of March 31, 2024, compared to CNY 483,752,548.96 at the end of 2023[10]. - Current assets totaled ¥269,303,061.08, down from ¥288,548,465.84, indicating a decrease of about 6.7%[35]. - Total liabilities decreased to ¥183,453,540.30 from ¥194,772,060.38, a reduction of about 5.8%[37]. - Current liabilities totaled ¥135,034,105.69, down from ¥146,892,991.61, indicating a decrease of approximately 8.1%[36]. - The company's equity attributable to shareholders decreased to ¥279,925,023.51 from ¥288,980,488.58, a decline of approximately 3.1%[37]. Cash Flow - Cash flow from operating activities showed a net outflow of CNY 16,709,112.46, a decrease of 60.50% compared to the previous year[12]. - In Q1 2024, the company's cash inflow from operating activities was CNY 34,138,228.48, a decrease of 24.5% compared to CNY 45,226,729.90 in Q1 2023[47]. - The net cash outflow from operating activities was CNY -16,709,112.46, worsening from CNY -10,410,561.45 in the same period last year[47]. - Total cash outflow from investing activities was CNY 35,338,156.89, significantly higher than CNY 2,073,032.77 in Q1 2023[48]. - The net cash flow from financing activities was CNY -3,733,643.00, compared to a positive cash flow of CNY 8,377,239.50 in Q1 2023[48]. - The ending cash and cash equivalents balance decreased to CNY 32,615,808.69 from CNY 84,332,332.63 year-over-year[48]. Expenses - Research and development expenses surged by 135.22% to CNY 6,033,462.71, driven by investments in the development of magnetic materials and superconducting magnets[12]. - Sales expenses increased by 93.49% to CNY 7,432,956.77 due to the establishment of a new sales team for 1.5T superconducting MRI machines[12]. - Total operating costs increased to ¥30,698,379.49 in Q1 2024, up 20.9% from ¥25,391,793.23 in Q1 2023[42]. - Cash paid for purchasing goods and services was CNY 24,500,663.93, down from CNY 29,161,540.28 in the previous year[47]. - The cash outflow for employee compensation increased to CNY 16,586,868.00 from CNY 14,345,914.08 in Q1 2023[47]. Shareholder Information - The total number of ordinary shares remained at 85,847,126, with 60.84% being unrestricted shares[17]. - The largest shareholder, Wang Jie, holds 27.22% of the shares, totaling 23,365,988 shares[20]. - The total shares held by the top ten shareholders account for 54.38% of the company's total shares, amounting to 46,687,659 shares[20]. - There are no pledged or judicially frozen shares among the top shareholders[22]. Commitments and Guarantees - The company has provided external guarantees totaling ¥10,000,000, with a current balance of ¥3,650,000[26]. - Wang Jie has signed a maximum guarantee contract with China Construction Bank for ¥90,000,000, with a current borrowing balance of ¥70,300,000[28]. - The company has fulfilled all disclosed commitments in a timely manner[24]. - The company has no significant related party transactions that were not disclosed[24]. - The company has no plans for share repurchase or employee incentive plans during the reporting period[24]. Other Information - The company has no litigation or arbitration matters reported during the period[24]. - Non-recurring gains and losses amounted to CNY 687,606.71 after tax for the reporting period[14]. - The company reported a significant increase in prepayments by 579.44% to CNY 8,381,959.17, attributed to increased raw material procurement[11]. - The company reported a significant increase in development expenditures to ¥876,271.96 from ¥348,183.06, an increase of approximately 151.5%[36].
辰光医疗(430300) - 2024 Q1 - 季度财报